News

Call deadline postponed to 24 September 2026

Published on | 2 weeks ago

Programmes
Culture and society

Below you can find some guidance for the IT issues.

Please note that the call deadline for the 2026 calls of Horizon Europe Cluster 2 has been postponed from 23 September to 24 September 2026 17:00:00 Brussels time due to IT issues.

Do not wait until the deadline with your first submission! If you face IT problems, please make sure to contact the IT helpdesk for an official follow-up.

The European Commission additionally communicated the following advice in case your are encountering IT issues during the submission of the proposal:

  • Check the guidance.
  • If there is no blocking error, you can submit and improve your proposal later.
  • Always contact the helpdesk if you face technical issues (and make sure to keep a Part B that`s saved before the deadline).

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

2026 articles available search in articles 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.